CIMP是一类基因组中有高比例的基因启动子区发生了DNA高甲基化的CRC. 目前研究显示CIMP具有多个分子水平的特征, 而且CIMP与多个临床特征显著相关, 但是还不清楚CIMP的具体致病原因和发病机制.

2024年9月5日 · Here, we investigated the differential features of the tumor immune microenvironment according to CIMP status in MSI-H CRCs. CIMP-high (CIMP-H) or CIMP-low/negative (CIMP-L/0) status was determined using MethyLight assay in 133 MSI-H CRCs.

One study, focused on lung adenocarcinomas [133], identified a higher frequency of methylation of the gene CDKN2A on proximal inflammatory tumors and classified the tumors into H-CIMP, L-CIMP and intermediate CIMP [133].

2024年10月15日 · CIMP状态是基于对五个基因甲基化水平的评估确定的，至少三个基因的甲基化被认为是CIMP高，而一个或两个基因的甲基化被认为是CIMP低 [17,18]。 还提出了其他基因面板 [19]，这在比较不同研究中的CIMP状态时提出了挑战。

2008年3月1日 · The CpG island methylator phenotype-high (CIMP-high) was defined as the presence of ≥6/8 methylated (positive) loci, CIMP-low as the presence of 1/8 to 5/8 methylated loci, and CIMP-0 as the absence (0/8) of methylated loci based on the data that CIMP-high and CIMP-low are associated with BRAF mutation and KRAS mutation, respectively. 10, 17 ...

此型约占13%，多位于右半结肠，病理学上多表现为中、高分化的乳头状肿瘤，具有显著的代谢失调特征，是结直肠癌分子亚型中唯一存在KRAS基因高频度突变的亚型，并以 KRAS基因突变 为主要特征。 CIMP CpG 岛甲基化表型 （CpG island methylator phenotype，CIMP）和CIN染色体不稳定性（chromosome instability，CIN）的水平较低、30%的个体还具有 MSI特征。 CMS-3-代谢型肿瘤的免疫原性同样较低，但患者整体预后较好 。 KRAS基因是指南中少见的对治疗有指 …

目的 CpG岛甲基化表型 (CpG Island Methylator Phenotype, CIMP)是一种具有不同临床特征和分子特征的结直肠癌类型,其涉及到多个基因位点的同时甲基化.近些年的研究普遍认为CIMP在包括结直肠癌在内的许多恶性肿瘤的发生发展机制中都起到了重要作用,并且其与结直肠癌 ...

Additionally, there is a distinct subset of CRCs, known as the CpG island methylator phenotype (CIMP) [133]; CIMP tumors frequently carry BRAFV600E mutations [134]. CIMP is further subclassified based on integrated genetic and epigenetic instability into CIMP2, CIMP-low, and CIMP-high [135, 136].

In this study using quantitative DNA methylation analysis (MethyLight) and a large number of population-based colorectal cancer specimens, we have evaluated performance characteristics of eight methylation markers including CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1 as well as CDKN2A (p16), CRABP1, and MLH1.

Low-level methylation (methylation index>0, <20) in each CIMP-high-specific locus was significantly more common in 340 CIMP-low tumors (1/8-5/8 methylation-positive loci) than 133 CIMP-high tumors (> or =6/8 methylation-positive loci) and 416 CIMP-0 tumors (0/8 methylation-positive loci) (P< or =0.002).